Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

August 17, 2015 08:05 ET | Source: Amarantus BioScience Holdings, Inc.

Amarantus Reports Second Quarter 2015 Financial Results and Business Overview

SAN FRANCISCO and GENEVA, Aug. 17, 2015 (GLOBE NEWSWIRE) -- Amarantus BioScience Holdings, Inc. (OTCQX:AMBS), a biotechnology company developing therapeutic and diagnostic product candidates in orphan...
August 07, 2015 17:05 ET | Source: Amarantus BioScience Holdings, Inc.

Amarantus Announces Adjournment of Annual Meeting

SAN FRANCISCO and GENEVA, Aug. 7, 2015 (GLOBE NEWSWIRE) -- Amarantus BioScience Holdings, Inc. (OTCQX:AMBS), a biotechnology company developing therapeutic and diagnostic product candidates in orphan...
August 05, 2015 08:50 ET | Source: Amarantus BioScience Holdings, Inc.

Amarantus Announces a New Eltoprazine Publication Confirming the Long-Term Efficacy and Elucidating the Mechanism of Action in PD-LID

Latest preclinical data in the peer-reviewed journal 'Movement Disorders' support previous nonclinical and clinical findings that eltoprazine is effective against Parkinson's Disease L-dopa...
August 03, 2015 17:30 ET | Source: Amarantus BioScience Holdings, Inc.

Amarantus Announces Adjournment of Annual Meeting

SAN FRANCISCO and GENEVA, Aug. 3, 2015 (GLOBE NEWSWIRE) -- Amarantus BioScience Holdings, Inc. (OTCQX:AMBS), a biotechnology company developing therapeutic and diagnostic product candidates in orphan...
August 03, 2015 06:00 ET | Source: Amarantus BioScience Holdings, Inc.

Amarantus BioScience, U.S. Army and Rutgers University in Partnership to Expand Development of Engineered Skin Substitute (ESS) for the Treatment of Severe Thermal Burn Wounds

SAN FRANCISCO and GENEVA, Aug. 3, 2015 (GLOBE NEWSWIRE) -- Amarantus BioScience Holdings, Inc. (OTCQX:AMBS), a biotechnology company developing therapeutic and diagnostic product candidates in orphan...
July 29, 2015 07:35 ET | Source: Amarantus BioScience Holdings, Inc.

Amarantus Announces Publication of a Clinical Study of MSPrecise(R) Diagnostic for Identification of Relapsing-Remitting Multiple Sclerosis (RRMS) in the Journal GENE

- MSPrecise next generation sequencing assay supports identification of multiple sclerosis patients with 84% accuracy - - Results from this study were not combined with oligoclonal banding (OCB)...
July 27, 2015 07:35 ET | Source: Amarantus BioScience Holdings, Inc.

Amarantus Diagnostics Establishes Strategic Advisory Committee

SAN FRANCISCO and GENEVA, July 27, 2015 (GLOBE NEWSWIRE) -- Amarantus Diagnostics, a neurology-focused diagnostics company developing diagnostic tests for multiple sclerosis and Alzheimer's disease...
July 22, 2015 10:30 ET | Source: Amarantus BioScience Holdings, Inc.

Amarantus Diagnostics Meets Primary and Secondary Endpoints in Blinded, Multi-Center LP-002 Clinical Study for LymPro(R) Blood Diagnostic for Alzheimer's Disease and Confirms LymPro's Fit-For-Purpose Use in Clinical Trials at the 2015 Alzheimer's Association International Conference(R)

LymPro discriminates Alzheimer's disease (AD) from healthy controls with comparable accuracy to clinical diagnosis reference standard Data corroborate previously published...
July 20, 2015 07:05 ET | Source: Amarantus BioScience Holdings, Inc.

Amarantus Announces First Patient Dosed in Eltoprazine Phase 2b Study for Treatment of Parkinson's Disease Levodopa-Induced Dyskinesia

SAN FRANCISCO and GENEVA, July 20, 2015 (GLOBE NEWSWIRE) -- Amarantus BioScience Holdings, Inc. (OTCQX:AMBS), a biotechnology company developing therapeutic and diagnostic product candidates in orphan...
July 15, 2015 07:05 ET | Source: Amarantus BioScience Holdings, Inc.

Amarantus Completes Acquisition of ESS From Lonza for the Treatment of Severe Burns

SAN FRANCISCO and GENEVA, July 15, 2015 (GLOBE NEWSWIRE) -- Amarantus BioScience Holdings, Inc. (OTCQX:AMBS), a biotechnology company focused on developing therapeutic and diagnostic products for...

keyboard_arrow_left Previous Page

Next Page keyboard_arrow_right